XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. It is a water-soluble macromolecular conjugate of camptothecin (CPT). In this novel CPT... In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal).
- Mechanism
- Curator reviewed
XMT-1001 is Mersana’s most advanced Fleximer®-based product candidate. It utilizes a novel, dual release mechanism to liberate a camptothecin prodrug, which is then converted within cells into camptothecin, a DNA topoisomerase I inhibitor. It is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model.
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Code names
- XMT-1001
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with XMT-1001, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account